Keensight Capital invests in Cardiff-Based CatSci Ltd Keensight Capital, a leading private equity manager dedicated to pan-European growth buyout[2] investments, has invested in CatSci Ltd, a Contract Research Organisation (CRO) that supports leading global pharmaceutical companies to deliver life-changing the.
Pharmaceutical innovation partner CatSci Ltd, a winner of the Bionow Awards Export of the Year Award, has described the prestigious accolade as a huge honour for the company, which reflected the hard work, commitment and talent of the whole team behind the success of its internationalisation strategy. Click to read more.
CatSci Ltd are incredibly delighted to announce that we have won the coveted Queen’s Awards For Enterprise: International Trade 2022. The Queen’s Awards for Enterprise are the most prestigious business awards in the UK, and winning this accolade is a huge achievement for CatSci. We are incredibly pr.
May 17 2021
Medicines development specialist CatSci Ltd has commissioned a new material science laboratory as part of its £3 million investment plan to expand its integrated drug development capabilities. The new lab, expected to be open at the beginning of June 2021, will provide solid state expertise for both emerging and established pharma companies.
Dr Ross Burn, CEO, said: “Expanding our material science capabilities will enable us to provide a fully sustainable, integrated solution that will ultimately de-risk our customers’ pharmaceutical pipeline. Our agile, end-in-mind approach adds true value to both our core customer segments: it helps maximise the chance of small molecule success for emerging pharma companies and by taking a data-rich approach earlier in the process, we can minimise risks in the latter stages of drug development for large pharma companies.”